HYBRID EVENT: Join us in person in Rome, Italy or attend virtually from anywhere.

13th Edition of International Conference on

Neurology, Brain Health & Neurological Disorders

June 24-26, 2027 | Rome, Italy

Genetics In Neurodegenerative Disorder

Genetics In Neurodegenerative Disorder

Neurodegenerative diseases refer to a group of progressive conditions that cause the neurons in the brain and spinal cord to deteriorate over time. These diseases not only cause physical and cognitive impairments but also lead to significant emotional stress and an overall decline in quality of life. Over the last few years, genetics has been pinpointed as an obvious factor in the pathogenesis of these diseases. The discovery of genetic links to neurodegenerative disorders has led to an increased focus on the role of genetic risk factors in disease susceptibility. Genetic mutations, deletions, and alterations have been identified for many neurodegenerative diseases, such as Huntington’s disease, Alzheimer’s disease, and Parkinson’s disease. For instance, the Huntington’s disease-causing CAG repeat mutation is located in the Huntington’s gene. This gene codes for the enzyme Huntingtin, which is found in large concentrations in the brain and implicated in the disease pathogenesis. Parkinson’s disease is linked to several mutations on at least four genes. The most important of these is the LRRK2 gene, which carries a greater risk of developing Parkinson’s compared to other genes. For Alzheimer’s disease, a mutation in the ApoE gene has been found to increase the risk of developing the disease. Furthermore, other genes implicated in the disease's risk include APP, PSEN1, and PSEN2. With the advancements in genetic research and testing, doctors and scientists may be able to develop preventive strategies, appropriate treatments, and even cures for neurodegenerative disorders. The insight gained from genetic studies can help researchers design targeted therapies, unravel pathways involved in the pathogenesis of such diseases, and help patients make informed decisions regarding their health. At the same time, genetic testing for neurodegenerative diseases does come with certain risks, such as having to cope with an unexpected diagnosis, stigma, and anxiety. Thus, genetic testing should only be conducted after taking into consideration the emotional and physical impact it may have on an individual.

Committee Members
Speaker at  Neurology, Brain Health & Neurological Disorders 2027 - Yong Xiao Wang

Yong Xiao Wang

Albany Medical College, United States
Speaker at  Neurology, Brain Health & Neurological Disorders 2027 - Sid O Bryant

Sid O Bryant

Texas College of Osteopathic Medicine and University of North Texas Health Science Center Fort Worth, United States
Speaker at  Neurology, Brain Health & Neurological Disorders 2027 - W S El Masri

W S El Masri

Keele University, United Kingdom
Neurology 2027 Speakers
Speaker at  Neurology, Brain Health & Neurological Disorders 2027 - Luiz Moutinho

Luiz Moutinho

University of Suffolk, United Kingdom
Speaker at  Neurology, Brain Health & Neurological Disorders 2027 - Bernd Blobel

Bernd Blobel

University of Regensburg, Germany
Speaker at  Neurology, Brain Health & Neurological Disorders 2027 - Salvador Ventura

Salvador Ventura

Autonomous University of Barcelona, Spain
Speaker at  Neurology, Brain Health & Neurological Disorders 2027 - Zhenhuan Liu

Zhenhuan Liu

Guangzhou University of Chinese Medicine, China
Tags

Submit your abstract Today

Watsapp